Clinical research

Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol

Michael Billinger, Lorenz Raeber, Christian Seiler, Stephan Windecker, Bernhard Meier, Otto M. Hess

Cardiology, Swiss Cardiovascular Centre, University Hospital, CH-3010 Bern, Switzerland

Received 17 April 2003; revised 30 January 2004; accepted 5 February 2004

See page 537 for the editorial comment on this article

Background The use of ultrathin Doppler angioplasty guidewires has made it possible to measure collateral flow quantitatively. Pharmacologic interventions have been shown to influence collateral flow and, thus, to affect myocardial ischaemia.

Methods Twenty-five patients with coronary artery disease undergoing PTCA were included in the present analysis. Coronary flow velocities were measured in the ipsilateral (n = 25) and contralateral (n = 6; two Doppler wires) vessels during PTCA with and without i.v. adenosine (140 μg/kg.min) before and 3 min after 5 mg metoprolol i.v., respectively. The ipsilateral Doppler wire was positioned distal to the stenosis, whereas the distal end of the contralateral wire was in an angiographically normal vessel. The flow signals of the ipsilateral wire were used to calculate the collateral flow index (CFI). CFI was defined as the ratio of flow velocity during balloon inflation divided by resting flow.

Results Heart rate and mean aortic pressure decreased slightly (ns) after i.v. metoprolol. The collateral flow index was 0.25 ± 0.12 (one fourth of the resting coronary flow) during the first PTCA and 0.27 ± 0.14 (ns versus first PTCA) during the second PTCA, but decreased with metoprolol to 0.16 ± 0.08 (p < 0.0001 vs. baseline) during the third PTCA.

Conclusions Coronary collateral flow increased slightly but not significantly during maximal vasodilatation with adenosine but decreased in 23 of 25 patients after i.v. metoprolol. Thus, there is a reduction in coronary collateral flow with metoprolol, probably due to an increase in coronary collateral resistance or a reduction in oxygen demand.

© 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.

Introduction

Coronary collateral circulation is an important pathophysiological mechanism to supply blood to a myocardial area jeopardised by an occluded or stenotic artery. The functional relevance of coronary collaterals in humans has been a matter of debate for many years.1-3 Previous studies have demonstrated a protective role of collaterals in patients with coronary artery disease, which show a smaller infarct size,4 less ventricular aneurysm formation, improved ventricular function,4,5 and better survival6 compared to patients without collaterals. Much of the controversy about collaterals is due to inadequate

* Corresponding author. Tel.: +41-31-632-9652/3693; fax: +41-31-632-4771.
E-mail address: otto.martin.hess@insel.ch (O.M. Hess).


0195-668X/$ - see front matter © 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
doi:10.1016/j.ehj.2004.02.003
methods to determine collateral blood flow. Semiquantitative (angiographic) methods have been used to estimate the extent of coronary collaterals\(^1\) or acutely recruitable collaterals during angioplasty.\(^7\) Intracoronary Doppler wires have been used to measure flow velocity in patients with coronary stenosis\(^9\) - \(^11\) and collaterals.\(^12\) - \(^15\) The theoretical basis for the use of intracoronary flow velocity measurements to determine collateral flow relates to the fact that velocity signals distal to an occluded stenosis almost invariably originate from collaterals.

Physical exercise, mental stress, and drugs influence collateral flow. The effect of cardioselective $\beta$-blockers such as metoprolol has not yet been studied, although this class of drugs favourably influences the occurrence of myocardial ischaemia by reducing myocardial oxygen consumption. On the other hand, $\beta$-blockers increase coronary vascular resistance\(^16\) and thus may diminish collateral perfusion, aggravating myocardial ischaemia. Thus, the purpose of the present study was to assess coronary collateral flow before and after adenosine infusion and with and without intravenous $\beta$-blockade.

### Methods

#### Patients

Twenty-five patients (age 58 ± 10 years, all men) with one- or two-vessel disease were included in the present analysis (Table 1). Five of the 25 patients had previous myocardial infarction in the non-PTCA perfusion territory and none of these patients had a Q-wave infarct. All patients underwent percutaneous transluminal coronary angioplasty (PTCA) for clinical motives (angina pectoris or positive exercise test with ST-segment depression). The percent diameter stenosis of the dilated vessel was 83 ± 10% before and 6 ± 8% after the intervention. Cardiovascular risk factors and preintervention medication are summarised in Table 1.

Inclusion criteria: Patients with coronary artery disease and angina pectoris, age 18–80 years, indication for PTCA, written informed consent, and absence of allergy to adenosine or metoprolol.

Exclusion criteria: Unstable angina pectoris and myocardial infarction (< 2 months), hypertension with left ventricular hypertrophy, tortuous coronary arteries, women of childbearing age, or $\beta$-blocker treatment.

This investigation was approved by the local ethics committee.

#### Power calculation

The appropriate sample size for the present study was assessed by power analysis. A decrease in collateral flow index from 0.25 to 0.20 after metoprolol would require a sample size of 10 patients (assuming a standard deviation of the difference between the two CFI values of 0.05; power: 80%; $p < 0.05$).\(^{15}\) With 16 patients, a power of 96% would be achieved.

### Coronary angiography

Patients underwent left heart catheterisation for diagnostic purposes. Aortic pressure was measured using the PTCA guiding catheter. Biplane left ventricular angiography was performed followed by diagnostic coronary angiography. Coronary artery lesions were estimated quantitatively as percent diameter reduction. Coronary collateral flow was assessed by the Rentrop score.\(^8\)

### Doppler flow velocity measurements

Doppler flow velocity measurements were performed using a 0.014 inch (1/3 mm in diameter) PTCA Doppler guidewire with a 12-MHz piezoelectric crystal at its tip (FloWire\(^{10}\), EndoSonics, Rancho Cordova, California, USA). The validation of this Doppler guidewire has been described previously.\(^10\)

The collateral flow index (CFI) was determined as the ratio of the flow velocity time integral distal to the occluded artery during balloon dilatation divided by baseline flow velocity obtained at the same location prior to PTCA (Fig. 1).\(^{15}\) In a subgroup of 6 patients, contralateral and ipsilateral flow velocity was measured in a normal (contralateral) and a "stenotic" (ipsilateral) vessel segment. A peripheral vein was used for fluid application and adenosine infusion.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>25</td>
<td>–</td>
</tr>
<tr>
<td>Age (years)</td>
<td>58 ± 10</td>
<td>–</td>
</tr>
<tr>
<td>Men</td>
<td>24</td>
<td>96</td>
</tr>
<tr>
<td><strong>Cardiovascular risk factors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>11</td>
<td>44</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>6</td>
<td>24</td>
</tr>
<tr>
<td>Obesity</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Hypertension</td>
<td>11</td>
<td>44</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>6</td>
<td>24</td>
</tr>
<tr>
<td><strong>Medication</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>21</td>
<td>84</td>
</tr>
<tr>
<td>$\beta$-Blockers</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Lipid lowering agents</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>7</td>
<td>28</td>
</tr>
<tr>
<td>Nitrates</td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td><strong>Vessel studied</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD/LCX/RCA</td>
<td>12/5/8</td>
<td>48/20/32</td>
</tr>
<tr>
<td>% Diameter stenosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-PTCA (%)</td>
<td>83 ± 10</td>
<td></td>
</tr>
<tr>
<td>Post PTCA (%)</td>
<td>6 ± 8</td>
<td></td>
</tr>
</tbody>
</table>
Study protocol

After diagnostic coronary angiography, an interval of at least 10 min was allowed for dissipation of the effect of the nonionic contrast medium (iopamidol 755 mg/300 mg iodine) on coronary flow velocity and vasomotion. An intracoronary (ic) bolus of 0.2 mg of nitroglycerin was given to keep the calibre of the epicardial coronary artery constant, and thus eliminate dimensional changes in the epicardial vessels that could influence flow indices. The Doppler guidewire was positioned distal to the stenosis to be dilated, and coronary flow velocity reserve measurements were obtained. Flow velocity was measured in 12 patients in the left anterior descending, in 5 in the circumflex, and in 8 in the right coronary artery (Table 1). Collateral flow velocity was measured continuously during the first balloon occlusion without adenosine (PTCA 1) and during a second occlusion with i.v. adenosine (PTCA 2). Then, 5 mg metoprolol was administered intravenously over 5 min. After an interval of 5 min, collateral flow velocity was measured continuously during the first balloon occlusion without adenosine (PTCA 1) and during a second occlusion with i.v. adenosine (PTCA 2). Then, 5 mg metoprolol was administered intravenously over 5 min. After an interval of 5 min, collateral flow velocity was determined during a third balloon occlusion, at first without and then with i.v. adenosine (PTCA 3, Fig. 2). Before each balloon inflation, resting flow velocity was determined at the same location as during balloon occlusion (baseline measurement). Intravenous adenosine infusion was associated with an increase in coronary flow as early as 15–20 s. An intracoronary ECG was recorded from the Doppler guidewire and 3 standard ECG leads were recorded. Blood pressure was measured continuously with the guiding catheter at the ostium of the coronary artery. During balloon occlusion, 16 of the 25 patients showed ST-segment changes in the intracoronary ECG but only half of them had clinical symptoms (anginal pain).

In 6 of the 25 patients a second Doppler wire was introduced in the contralateral vessel to study flow changes in an angiographically normal vessel segment. Coronary flow velocity was measured at rest and during PTCA and adenosine infusion in both the ipsilateral and contralateral vessel segments. The contralateral vessel segment served as a control region for flow changes during the study protocol.

Statistical analysis

Comparison of angiographic, haemodynamic, and Doppler flow velocity data was performed by an analysis of variance (ANOVA) for repeated measurements. Data were analysed at baseline, after adenosine infusion, and after metoprolol administration. Only fixed, no random, effects were included. There was one treatment group. A saturated model was used with different estimates of the mean, but no assumption was made as to whether a time point was baseline or a PTCA measurement. The covariance structure was used to account for the dependence of coronary collateral flow between different measurements of a single patient. Regarding the covariance matrix, a check of the correlation coefficients between the different measurements indicated that compound symmetry is a reasonable assumption. In addition to the model-based estimates as given in the manuscript, we also calculated empirical standard errors, for which it has been shown that the results are valid even if the covariance matrix is misspecified. There was no material difference in the results. Statistical significance was defined as a p-value of < 0.05.

Results

Representative flow velocity recordings during and after balloon inflation are shown in Fig. 1. During balloon occlusion (left panel), flow velocity dropped from 18 to 6.9 cm/s but increased after balloon deflation (= postischaemic hyperaemia; middle panel) to 53 cm/s. After

Study Protocol

Fig. 2 Study protocol: Prior to coronary flow measurements, 200 µg nitroglycerin is administered for maximal vasodilatation. Then three consecutive balloon inflations (60 s each) are performed (PTCA 1–3). 1st PTCA: Control inflation, 2nd PTCA: Adenosine infusion, 3rd PTCA: Metoprolol administration followed by adenosine infusion during balloon inflation.
Flow velocity decreased significantly during PTCA 1, 2 and 3, respectively. Coronary flow was unchanged between balloon inflations, i.e., there was no significant change in coronary flow between baseline 1–4 (Table 3). Adenosine had only a minor effect on coronary flow velocity during PTCA. However, in 8 patients there was a mild decrease in coronary flow velocity, which was not significant when compared to the other patients. After 5 mg intravenous metoprolol, coronary flow velocity decreased in 23 of the 25 patients during PTCA. This flow velocity (PTCA 3) was significantly lower than during PTCA 1 or 2. Baseline flow velocity remained, however, unchanged during metoprolol. There were no differences between vascular beds, i.e., between the left anterior descending and right coronary artery.

In 6 of the 25 patients, the coronary flow velocity of the ipsilateral ("stenotic") and contralateral (normal) vessel was measured simultaneously. Despite a significant increase in the flow velocity of the contralateral vessel (from 19 ± 7 to 41 ± 9 cm/s), no effect on ipsilateral flow velocity was observed after i.v. adenosine, but a significant drop in ipsilateral flow velocity (from 3.6 ± 1.9 to 2.5 ± 1.5 cm/s) was found after metoprolol during pharmacologic hyperaemia (Fig. 4).

Collateral flow index

The collateral flow index was similar during PTCA 1 (0.25 ± 0.20) and 2 (0.27 ± 0.14) with and without adenosine. However, after metoprolol infusion, adenosine led to a significant fall in collateral flow index (0.16 ± 0.06), indicating a reduction in coronary collateral flow following i.v. β-blockade (Fig. 3).

Discussion

Coronary collateralisation plays an important role in the pathophysiology of myocardial ischaemia and limits the size of myocardial infarction in patients with coronary artery disease. Sudden occlusion of the supply...
artery (plaque rupture) is usually associated with larger infarcts than in chronic coronary artery disease because coronary circulation does not have enough time to develop collaterals. Coronary collaterals may occur with repeated ischaemia or during exercise training. In the presence of a high-grade stenosis, however, collateral flow is dependent on coronary vasomotor tone and decreases with vasoconstrictor agents or changes in coronary perfusion pressure. Thus, the purpose of the present study was to assess coronary collateral perfusion before and after \( \beta \)-blockade in patients with coronary artery disease undergoing PTCA for therapeutic reasons. Collateral flow velocity was measured with a Doppler wire during balloon inflation using i.v. adenosine to induce maximal coronary vasodilatation of collateral-dependent and collateral-supplying arteries.

**Coronary collateral flow with metoprolol**

The coronary collateral flow index increased slightly during the intravenous administration of adenosine (Fig. 3) in 13 of 25 patients, but remained unchanged or even decreased in 12 patients. These changes did, however, not reach statistical significance. After metoprolol, the collateral flow index decreased significantly when adenosine was given intravenously (Fig. 3). Two thirds (16) of all patients showed ST-segment changes in the intracoronary ECG during balloon occlusion. Half of these patients developed anginal pain which was due to either ischaemia or adenosine-induced chest discomfort that could not be differentiated. Despite the fall in collateral flow after metoprolol, during adenosine infusion no more patients developed anginal pain. This can be explained either by the small extension of the ischaemic zone or by the preponderance of the oxygen-saving mechanism of metoprolol with a significant reduction in the rate-pressure product (Table 2). The fall in collateral flow could be due either to metoprolol directly (increase in resistance) or due to the decrease in oxygen requirements (decrease in the rate-pressure product). Other mechanisms may also have been involved, such as preconditioning of the ischaemic myocardium by repeated balloon inflation or stunning of the myocardium at risk. Previous experimental and clinical data have shown that during sympathetic activation coronary collateral perfusion increases due to the reduction in the pressure gradient across the collateral vessel. By analogy, the application of a \( \beta \)-blocker leads to an increase in coronary collateral resistance. This may explain why collateral flow velocity decreases after metoprolol. However, in the daily clinical setting, \( \beta \)-blockers have been rarely associated with an increase in symptoms. Therefore, the decrease in coronary collateral flow may be associated with a reduction in myocardial oxygen consumption induced by the decrease in the rate-pressure product.

In 6 of the 25 patients, the coronary flow velocity of the ipsilateral ("stenotic") and contralateral (normal) vessels was measured simultaneously. Despite a significant increase in flow velocity of the contralateral vessel (from 19 ± 7 to 41 ± 9 cm/s), the collateral flow of the ipsilateral vessel did not increase during balloon occlusion after i.v. adenosine. In contrast, there was a drop in ipsilateral flow velocity from 3.6 ± 1.9 to 2.5 ± 1.5 cm/s after metoprolol during adenosine (Fig. 4). Thus, the contralateral vessel shows a typical hyperaemic response, whereas the ipsilateral occlusive flow velocity (i.e., collateral flow) decreased after metoprolol in 23 of the 25 patients.

Thus, the reduction in coronary collateral flow after metoprolol appears to be due to a vasoconstrictive response of the collateral vessel with an increase in vascular resistance.

**Limitations**

Several potential limitations of the present study should be considered.

(1) The exact mechanism responsible for the reduction in coronary collateral flow after metoprolol is not clear but may require adjustment of the heart rate and blood pressure to keep one of the determinants of collateral flow constant.

(2) The effect of i.v. metoprolol on heart rate and blood pressure was relatively modest. This would favour the hypothesis of a direct effect of metoprolol on collaterals rather than a secondary decrease in...
collateral flow due to the decrease in the rate-pres-

ure product.

References